{
  "id": "601cba001cb411341a000028",
  "type": "summary",
  "question": "What is the mechanism of action of idasanutlin?",
  "ideal_answer": "Idasanutlin is a small-molecule inhibitor of MDM2, a negative regulator of tumor suppressor p53.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/33302031",
    "http://www.ncbi.nlm.nih.gov/pubmed/30536898",
    "http://www.ncbi.nlm.nih.gov/pubmed/30158012",
    "http://www.ncbi.nlm.nih.gov/pubmed/30755442",
    "http://www.ncbi.nlm.nih.gov/pubmed/30647052",
    "http://www.ncbi.nlm.nih.gov/pubmed/27353420",
    "http://www.ncbi.nlm.nih.gov/pubmed/29768700",
    "http://www.ncbi.nlm.nih.gov/pubmed/26586447",
    "http://www.ncbi.nlm.nih.gov/pubmed/26993060",
    "http://www.ncbi.nlm.nih.gov/pubmed/30352966",
    "http://www.ncbi.nlm.nih.gov/pubmed/29392451",
    "http://www.ncbi.nlm.nih.gov/pubmed/32629830",
    "http://www.ncbi.nlm.nih.gov/pubmed/29368050",
    "http://www.ncbi.nlm.nih.gov/pubmed/30700046",
    "http://www.ncbi.nlm.nih.gov/pubmed/32020437",
    "http://www.ncbi.nlm.nih.gov/pubmed/30511219",
    "http://www.ncbi.nlm.nih.gov/pubmed/31289443",
    "http://www.ncbi.nlm.nih.gov/pubmed/29857559",
    "http://www.ncbi.nlm.nih.gov/pubmed/31734832",
    "http://www.ncbi.nlm.nih.gov/pubmed/32167393",
    "http://www.ncbi.nlm.nih.gov/pubmed/33190064",
    "http://www.ncbi.nlm.nih.gov/pubmed/31167802"
  ],
  "snippets": [
    {
      "text": "In our panel of ten cell lines with a spectrum of aberrations in the p53 and pRb pathway, idasanutlin and abemaciclib were the most potent MDM2 and CDK4/6 inhibitors, respectively. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33190064",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We evaluated idasanutlin-a new, potent murine double minute 2 antagonist-alone or with cytarabine in patients with r/r acute myeloid leukemia, de novo untreated acute myeloid leukemia unsuitable for standard treatment or with adverse features, or secondary acute myeloid leukemia in a multicenter, open-label, phase 1/1b trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33302031",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Idasanutlin is a selective small-molecule MDM2 antagonist. It activates the tumor suppressor TP53 and is in phase 3 clinical trial for acute myeloid leukemia. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30511219",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "High-risk neuroblastoma, a predominantly TP53 wild-type (wt) tumour, is incurable in >50% patients supporting the use of MDM2 antagonists as novel therapeutics. Idasanutlin (RG7388) shows in vitro synergy with chemotherapies used to treat neuroblastoma. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30536898",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The BCL2 inhibitor venetoclax plus the MDM2 inhibitor idasanutlin may be effective in treating relapsed/refractory acute myeloid leukemia. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30647052",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The small molecule RG7388 (idasanutlin, R05503781) is a newly developed inhibitor that is specific for an oncogene-derived protein called MDM2, which is also in clinical trials for the treatment of various types of cancers.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30700046",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31734832",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Purpose MDM2 is a negative regulator of the tumor suppressor p53. RO6839921 is an inactive pegylated prodrug of idasanutlin, an MDM2 antagonist, developed for intravenous administration. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31734832",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RO6839921 is an inactive pegylated prodrug of the oral MDM2 antagonist idasanutlin (active principle [AP]) that allows for IV administration. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32020437",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Idasanutlin is a small-molecule inhibitor of MDM2, a negative regulator of tumor suppressor p53. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32167393",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ter treatment of p53wt cells with idasanutlin (RG7388, RO5503781), which is the only MDM2 antagonist that has passed phase II and entered phase III clinical trials, so far. Idasanutlin strongly activates p53, as evidenced by the induction of p21 expression and pot",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30352966",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE: Idasanutlin is a selective small-molecule MDM2 antagonist.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30511219",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27353420",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "RO6839921 is an inactive pegylated prodrug of idasanutlin, an MDM2 antagonist, developed for intravenous administration.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31734832",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31289443",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "PURPOSE: Idasanutlin, a selective small-molecule MDM2 antagonist in phase 3 testing for refractory/relapsed AML, is a non-genotoxic oral p53 ac",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29368050",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "nd metastasis. The small molecule RG7388 (idasanutlin, R05503781) is a newly developed inhibitor that is specific for an oncogene-derived protein called MDM2, which is also in clinical trials for the treatment of various types",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30700046",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The BCL2 inhibitor venetoclax plus the MDM2 inhibitor idasanutlin may be effective in treating relapsed/refractory acute myeloid leukemia",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30647052",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "When combined with imidazoline MDM2 inhibitors (Nutlin-3a and Idasanutlin/RG-7388), synergism was observed in cancer cell growth inhibition.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32629830",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29368050",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "RO6839921 is an inactive pegylated prodrug of the oral MDM2 antagonist idasanutlin (active principle [AP]) that allows for IV administration.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32020437",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Idasanutlin (RG7388) is a potent p53-MDM2 antagonist currently in clinical development for treatment of cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26586447",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Efficient Industrial Synthesis of the MDM2 Antagonist Idasanutlin via a Cu(I)-catalyzed [3+2] Asymmetric Cycloaddition.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30158012",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Here we assessed the MDM2 antagonist idasanutlin and the MEK1 inhibitor cobimetinib as single agents and in combination in a variety of AML cell lines and primary AML blast cells for their ability to induce apoptosis and cell death.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29857559",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Investigating the effect of autoinduction in cynomolgus monkeys of a novel anticancer MDM2 antagonist, idasanutlin, and relevance to humans.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26586447",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "PURPOSE: Idasanutlin is a selective small-molecule MDM2 antagonist",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30511219",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE: Idasanutlin, a selective small-molecule MDM2 antagonist in phase 3 testing for refractory/relapsed AML, is a non-genotoxic oral p53 a",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29392451",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Therefore, we performed an investigator-initiated phase 1 trial of the oral MDM2 antagonist idasanutlin (RG7388; Roche) in patients with high-risk PV/ET for whom at least 1 prior therapy had failed.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31167802",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26993060",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "OBJECTIVES: To investigate whether the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) combined with the selective MDM2 antagonist idasanutlin (RG7388) offers superior efficacy to monotherapy in treating B-lymphoid malignancies in preclinical models.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26993060",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Venetoclax (ABT-199) and idasanutlin (RG7388) are efficient anticancer drugs targeting two essential apoptosis markers, Bcl-2 and MDM2, respectively. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29768700",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We discovered MDM2 and MDM4, the canonical negative regulators of p53, as significant vulnerabilities. Using two compounds currently in clinical development, idasanutlin (MDM2-specific) and ATSP-7041 (MDM2/4-dual), we show that MRT cells were more sensitive than other p53 wild-type cancer cell lines to inhibition of MDM2 alone as well as dual inhibition of MDM2/4. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30755442",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}